Company intelligence / Profile preview
Shanghai Cell Therapy Group
Shanghai, Shanghai Shi, Chinashcell.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Shanghai Cell Therapy Group is developing innovative cellular therapies for cancer and age-related diseases. Its lead program, BZDS‑1901, a bispecific CAR-T targeting mesothelin and PD‑1 for mesothelin-positive neoplasms, is in Phase 1 clinical trials. Another program targeting glioma has been discontinued. The company leverages expertise in stem cell rejuvenation and immune modulation to address oncology and anti-aging indications.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyCell therapyAutologous CAR-T
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
No major pharmaceutical partnerships publicly disclosed as of June 2025.
Beyond the preview
Go deeper on Shanghai Cell Therapy Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Cell Therapy Group.